Based on these reports, a therapy involving MUL1 inactivation, either by gene therapy or by developing a specific pharmacological inhibitor, could be useful to achieve cancer regression in breast cancer, lung cancer and glioma. The gene discussed is MUL1; the disease is central nervous system cancer.